Article

The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancer

2026-07-01

Abstract excerpt

<h4>Purpose</h4> There are no clinically validated biomarkers to assess recurrence risk and guide treatment de-escalation in Basal-like and HER2-enriched breast cancer. Taxane-based chemotherapy remains a cornerstone of treatment despite significant toxicity. We evaluated the prognostic and predictive utility of the MHCII Immune Activation Score (IA Score) in these subtypes. <h4>Experimental Design</h4> We retro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a51cecff-1790-5d48-8ef3-bfdedd0f2172
DOI: 10.64898/2026.06.24.26356102

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancerDOI 10.64898/2026.06.24.26356102Read

Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancerSemantic proximity Read

A Comprehensive Immunologic Portrait of Triple-Negative Breast CancerSemantic proximity Read

Immune checkpoints expression patterns predict prognosis and immune microenvironment remodeling in triple-negative breast cancerSemantic proximity Read

Genomic Features of Rapid Versus Late Relapse in Triple Negative Breast Cancer Semantic proximity Read

Immune Classification and Immune Landscape Analysis of Triple-Negative Breast CancerSemantic proximity Read

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscapeSemantic proximity Read

A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration.Semantic proximity Read

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis.Semantic proximity Read

Tumor-Infiltrating Lymphocytes Display Prognostic Signatures Associated with Chemotherapy Response in TNBC PatientsSemantic proximity Read

Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor BehaviorSemantic proximity Read

Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysisSemantic proximity Read

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.Semantic proximity Read